Collins Helen Louise bought ELVN
March 9, 2026 · Form 4 insider transaction
Collins Helen Louise bought 29,871 shares of Enliven Therapeutics, Inc. at $2.48 per share, a transaction worth $74.1K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
29,871
Price
$2.48
Total value
$74.1K
InsiderCollins Helen Louise
RoleOfficer, Director
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateMarch 9, 2026
Filing dateMarch 11, 2026
Shares owned after54,871
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.; Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.